Carcinoid and neuroendocrine tumours: Are we making any progress?

F. Murphy, W. J. Curry, N. Heaton, A. Stangou, M. Buxton-Thomas, J. K. Ramage*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


The investigation and management of neuroendocrine tumours is recognized to be a multidisciplinary process involving clinicians of many specialties. Chromogranin A has been accepted as a valuable immunohistopathological tissue marker for neuroendocrine tumours. The somatostatin analogues octreotide acetate and lanreotide are used to control symptoms and can improve quality of life. Surgery, transplantation, chemotherapy, embolisation and receptor targeted therapy all have a role to play in management. Given the longer length of survival of carcinoid patients, each is likely to need more than one type of treatment. These must be carefully chosen and the order in which they are offered to the patient carefully considered, rather than offering the treatment that is most readily available in that centre.

Original languageEnglish
Pages (from-to)63-68
Number of pages6
JournalCME Journal Gastroenterology, Hepatology and Nutrition
Issue number2
Publication statusPublished - 2001


  • Carcinoid tumour
  • Chromogranins
  • Neuroendocrine tumours
  • Octreotide
  • Somatostatin receptor subtypes


Dive into the research topics of 'Carcinoid and neuroendocrine tumours: Are we making any progress?'. Together they form a unique fingerprint.

Cite this